Publication at First Faculty of Medicine |
2019
Abstract
Familial hypercholesterolaemia (FH) is an hereditary disease that has been shown to increase the risk of atherosclerotic complications. The prevalence of FH among cardiac patients is higher than in the general population.
Due to achievable and very eff ective treatment, it is advisable that patients be diagnosed and adequately treated according to the level of cardiovascular risk. This can prevent cardiovascular complications due to progressing atherosclerosis.
The basis of the treatment is a highly dosed high-potency statin in combination with ezetimibe, and with PCSK-9 inhibitors if the payment criteria are met. Project MedPed (Make early diagnoses to Prevent early deaths in Medical Pedigrees) provides a care network for patients with FH.